Posts

A Brief History of MDMAShutterstock

A Brief History of MDMA: From the CIA to Raves to Psychedelic Therapy

,
The history of MDMA is fascinating, and it is still being written.
MAPS Navigates Multiple Scandals: Why Health Canada Is Reviewing MDMA TrialsShutterstock

MAPS Navigates Multiple Scandals: Why Health Canada Is Reviewing MDMA Trials

A sexual misconduct scandal, a data scandal, and an elder abuse scandal haunt psychedelics leader MAPS, currently being scrutinized by Health Canada.
5 Most Important Psychedelic Clinical Trials of 2022Shutterstock

5 Most Important Psychedelic Clinical Trials in 2022

Here's why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.
Can Psychedelics like MDMA Cure Eating Disorders?Shutterstock

Can Psychedelics like MDMA Cure Eating Disorders?

Anyone who has ever suffered from an eating disorder, such as anorexia or bulimia, knows that beating the mind virus is a constant struggle. While therapy can help some,...

Psychedelic Business Spotlight – February 18

,
This week in psychedelic business news: Nova Mentis makes progress on autism; atai donates to MAPS; Cathie Wood eyes more psychedelic stocks.

Interview with Rick Doblin, Executive Director and Founder of MAPS

In this episode, Rick and James Hallifax discuss MAPS’ work treating PTSD with MDMA, sending the Soviets Psychedelics, and what the future holds.
How MAPS Founder Rick Doblin Guides Someone Through a Bad Psychedelic TripShutterstock

How Rick Doblin Guides Someone Through a Bad Psychedelic Trip

Difficult trips could be a problem in areas where psychedelics have been decriminalized, which is why MAPS will offer a psychonaut training program.

2021: A Year in Review for the Psychedelics Business

Our resident Psychedelic Investor looks back at some of this growing industry's biggest moments and how they may shape the business in 2022.
Psychedelic Business Spotlight – December 17

Psychedelic Business Spotlight – December 17

,
This week in psychedelic business news: Cybin steps closer to a new patent; MindMed appoints new CEO; MAPS and Wesana Health resume negotiations.

Psychedelic Business Spotlight: December 3

,
This week in psychedelic business news: MAPS pioneers new funding structure; FDA green lights a Cybin study for Covid-19 distress; Compass Pathways gets new majority stakeholder.